Dual Immune Checkpoint Inhibitors in Advanced Cutaneous Melanoma

Sanjiv S. Agarwala, MD
Temple University School of Medicine
Philadelphia, PA

Dr Sanjiv Agarwala reviews data for first-line immunotherapy with nivolumab plus relatlimab demonstrating significantly improved progression-free survival over monotherapy, and a high pathologic complete response rate with this combination in the neoadjuvant setting, in patients with advanced melanoma. He also reviews data from the CheckMate-067 study showing durable 6.5-year overall survival with first-line nivolumab plus ipilimumab in patients with advanced melanoma.

Related Articles

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: